Table 1.
Results of base-case scenario.
| PCV13 | No vaccine | PPSV23 | |
|---|---|---|---|
| Overall number of PD episodes over the lifetime horizon in the population | |||
| Bacteremia or sepsis infections | 29,728 | 32,200 | 30,389 |
| Meningitis infections | 6,471 | 7,131 | 6,642 |
| Inpatient pneumonia | 2,372,771 | 2,396,994 | 2,397,043 |
| Outpatient pneumonia | 3,203,157 | 3,252,062 | 3,252,130 |
| Deaths for PD | 641,565 | 647,277 | 647,162 |
| Outcomes and costs per capita | |||
| LY | 15.206 | 15.202 | 15.202 |
| QALY | 12.048 | 12.045 | 12.045 |
| Costs (€) | 407.03 | 360.38 | 373.92 |
| Cost-effectiveness and costs-utility ratios | |||
| ICER | |||
| PCV13 vs. no vaccine | 11,082 €/LYG | ||
| PCV13 vs. PPSV23 | 8,151 €/LYG | ||
| ICUR | |||
| PCV13 vs. no vaccine | 17,746 €/QALY | ||
| PCV13 vs. PPSV23 | 13,146 €/QALY | ||
LY = Life-years; LYG = Life-year gained; QALY = Quality-adjusted life-years; ICER = Incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio.